This trial is testing whether cabozantinib and atezolizumab can shrink tumors in patients with metastatic castrate-resistant prostate cancer.
- Stage IV Prostate Cancer
- Castration-resistant Prostate Cancer
- Stage IVB Prostate Cancer
- Stage IVA Prostate Cancer
- Prostate Cancer
1 Primary · 5 Secondary · Reporting Duration: From trial initiation and death of any cause, assessed up to 5 years
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (cabozantinib, atezolizumab)
1 of 1
33 Total Participants · 1 Treatment Group
Primary Treatment: Cabozantinib S-malate · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Male Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What medical conditions is Cabozantinib S-malate typically employed to combat?
"Small cell lung cancer is typically treated with Cabozantinib S-malate, though it can also be utilized to help patients who have previously been exposed to anti-vegf treatments, or those that are diagnosed with a malignant neoplasm and deemed at high risk." - Anonymous Online Contributor
Is enrollment for this experiment still available to participants?
"Indeed, clinicaltrials.gov reports that this trial is actively recruiting participants. It was initially made available on March 11th 2022 and recently updated for the same date. The research team needs 33 individuals from a single location to take part in the study." - Anonymous Online Contributor
What sort of health hazards could be associated with Cabozantinib S-malate?
"Based on our evaluation at Power, Cabozantinib S-malate is given a score of 2 for safety. This is because it has been tested in Phase 2 trials and there is documentation supporting its safety but not yet any proof that the drug can effectively treat the condition." - Anonymous Online Contributor
Is this an inaugural clinical trial of its kind?
"As of now, 446 studies are active for Cabozantinib S-malate across 1911 cities and 75 countries. The initial trial involving this drug occurred in 2008 and was sponsored by Hoffmann-La Roche, recruiting 720 patients to complete its Phase 2 approval process. Subsequently, 135 trials have been finalized since then." - Anonymous Online Contributor
What is the current enrollment threshold for this clinical trial?
"Affirmative. The information hosted on clinicaltrials.gov implies that the trial is currently enrolling patients, which were first mentioned on March 11th 2022 and updated most recently in the same month. 33 participants are required for this study at 1 medical facility." - Anonymous Online Contributor